<code id='512A926790'></code><style id='512A926790'></style>
    • <acronym id='512A926790'></acronym>
      <center id='512A926790'><center id='512A926790'><tfoot id='512A926790'></tfoot></center><abbr id='512A926790'><dir id='512A926790'><tfoot id='512A926790'></tfoot><noframes id='512A926790'>

    • <optgroup id='512A926790'><strike id='512A926790'><sup id='512A926790'></sup></strike><code id='512A926790'></code></optgroup>
        1. <b id='512A926790'><label id='512A926790'><select id='512A926790'><dt id='512A926790'><span id='512A926790'></span></dt></select></label></b><u id='512A926790'></u>
          <i id='512A926790'><strike id='512A926790'><tt id='512A926790'><pre id='512A926790'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:comprehensive    - browse:6253

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus